Impact of Aging on Cytokine Production by Innate Immune Cells
NCT ID: NCT02660723
Last Updated: 2018-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2016-02-29
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longitudinal Innate Immunity and Aging Study
NCT03944603
MicroRNA Regulation of Chronic Inflammation During Aging
NCT05392582
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
NCT00995891
FIT to Grow Old - Functionality of the Immune System and Healthy Aging
NCT05940337
Genetic & Environmental Determinants Of Immune Phenotype Variance: A Longitudinal Assessment
NCT05381857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Volunteers
A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
Healthy Volunteers
A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Healthy Volunteers
A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* being between 18 and 30 year-old (group Y) or being older than 55 year-old (group O),
* ability to understand and speak French,
* being registered at the Social Security,
* acceptance to be serologically tested for HIV and HVC,
* considered healthy based on both past medical records and the clinical examination performed at the inclusion visit,
* exhibiting a body mass index (body mass divided by the square of their height) comprised between 18.5 and 30.0 kg/m2.
Exclusion Criteria
* having traveled to a tropical or a sub-tropical country over the past 3 months,
* being pregnant or a lactating mother (for women),
* having performed intensive physical exercise over the past 12 hours,
* following a specific diet for medical reasons,
* over-drinking, i.e. more that 50 g of pure alcohol every day,
* having taken an immuno-suppressive or immuno-modulatory drug over the past two weeks, or for at least 14 consecutive days over the past 6 months,
* having been vaccinated over the past 3 months,
* declaring not being on an empty stomach for less than 12 hours,
* having received a blood transfusion or intravenous immunoglobulins over the past 3 months,
* declaring being HIV- or HVC- positive,
* having suffered from an infection since less than 3 weeks,
* exhibiting a positive urine pregnancy test at the inclusion visit,
* suffering from a severe/chronic/relapsing pathology, i.e. inflammatory bowel disease, psoriasis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, type I or type II diabetes, Parkinson's disease, and (p) having been diagnosed with a cancer and not being in a remitting period for less than 5 years.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Passeron Thierry, PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Nice, Service de Dermatologie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nice, CRC, Hôpital de l'Archet 151 route de saint-antoine de ginestière
Nice, Alpes-Maritimes, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-PP-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.